The Asia-Pacific Cancer Biomarkers market is expected to reach USD XX million by 2020 growing at a CAGR of 16% from 2015 to 2020. Cancer biomarkers are substances that is an indicative of the presence of cancer in the body. Cancer biomarkers are secreted by a tumor or specific response of the body to the presence of Cancer. These are the substance that helps in detection of cancer and non- invasive diagnosis using genomics, proteomics techniques.
According to WHO, 8.2 million people die each year from Cancer, which is estimated to be 13% of all deaths globally. There is growing incidence of cancer in Asia-Pacific region. According to WHO, in India, in 2012, around 537000 women and 477000 men were diagnosed with cancer.
The rising use of cancer biomarkers for diagnostic purpose, preference towards non-invasive technologies, increasing government and private initiatives for biomarker discovery and rise in healthcare expenditure are propelling the growth of the market as key drivers. However, high cost of diagnostic procedures and unfavorable regulatory and reimbursement policies are turning out to be restraints for this market.
The Asia-Pacific biomarkers market have been segmented based on disease, applications, services, type and profiling technologies. The segmentation by disease have been subdivided into prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer and others. The segmentation based on applications have been subdivided into risk assessment, development of molecular diagnostics, disease diagnosis, drug discovery and development and drug formulation. The segmentation based on services have been subdivided into sample preparation, assay development and biomarkers validation. The segmentation based on type have been subdivided into protein biomarkers, genetic biomarkers and others (cell, Viral and Carbohydrate biomarkers).The Segmentation based on profiling technologies have been subdivided into Omics Technologies, imaging technologies, Immunoassays, cytogenetics, bioinformatics, and IVD multivariate index assays. The sub-segment on omics technologies include genomics, proteomics, metabolomics, transcriptomics, and pharmacogenomics. The sun-segment on immunoassay includes immunohistochemical (IHC) tests and flow cytometry.
The Asia-Pacific cancer biomarkers market have been geographically segmented into China, India, Japan, South Korea, Australia and New Zealand. The Asia-Pacific market is expected to grow at a fast pace with consistent economic development, increasing growth in healthcare facility, and rising prevalence of cancer. The Major Players in this cancer biomarkers market are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, EKF Diagnostics Holding, Merck and Co. Takeda Pharmaceuticals, Hologic Inc., PerkinElmer, Roche Diagnostics Corporation, BioMerieux, Cisbio bioassay, and Celera Corporation.
Key deliverables of the study: